Hi Technologies introduces Hilab, an innovator telemedicine service for laboratory tests

Curitiba, June 29, 2017 - Hi Technologies S.A., a company that, in 2016, had 50% of its capital acquired by Positivo Tecnologia S.A. (B3: POSI3), today introduced the Hilab, a telemedicine service that can perform laboratory tests for HIV, Zika virus, Chikunguya, dengue, hepatitis, pregnancy test, total cholesterol, HDL, glycated hemoglobin, vitamin D, glycemia, among others.

Almost painless and much faster than traditional methods, the Hilab service, developed with Microsoft and Intel technologies, which have also bet in this new sphere, introduces a new category in clinical analysis that combines internet of things and artificial intelligence to speed up medical diagnosis. The Hilab fits in the palm of the hand and uses only drops of blood from the patient‘s finger for the exam, with a less invasive mechanism. In addition, the results of the tests are shown in minutes, representing a small fraction of the time required by traditional methods, which may take a few days.

"We‘re bringing in three great innovations: the first medical tricorder in history, a disruptive telemedicine system, and a new big-data health technology. Hilab is a mix of all that. It brings the lab to the doctor‘s hand and this changes the health scenario", explains Marcus Figueredo, CEO of Hi Technologies.

To access the complete document, click here.

For additional information please contact Positivo Tecnologia‘s investor relations area:

Investor Relations
Tel.: +55 41 3316-7887
E-mail: ir@positivo.com.br
Website: www.positivotecnologia.com.br/ir